AstraZeneca’s LATIFY Study: A New Hope for NSCLC Treatment?

AstraZeneca ((AZN)), Parexel International ((PRXL)), AstraZeneca plc ((GB:AZN)), AstraZeneca ((DE:ZEGA)), AstraZeneca plc US ((AZNCF)) announced an update on their ongoing clinical study.

Study Overview: AstraZeneca, in collaboration with Parexel, is conducting a Phase III study titled ‘LATIFY’ to evaluate the efficacy and safety of ceralasertib plus durvalumab compared to docetaxel in patients with advanced or metastatic non-small cell lung cancer (NSCLC) who have progressed after prior anti-PD-(L)1 therapy and platinum-based chemotherapy. This study aims to provide an alternative treatment for patients without actionable genomic alterations, potentially improving outcomes in this challenging patient population.

Intervention/Treatment: The study tests two interventions: an experimental combination of ceralasertib, an oral drug, and durvalumab, an intravenous infusion, versus the standard care drug docetaxel, administered intravenously. The combination aims to enhance the immune response against cancer cells.

Study Design: This interventional study is randomized with a parallel assignment. It is open-label, meaning no masking is used, and its primary purpose is treatment-focused. Participants are divided into two groups: one receiving the experimental combination and the other receiving the standard treatment.

Study Timeline: The study began on September 15, 2022, and is currently active but not recruiting. The last update was submitted on August 14, 2025. These dates are crucial for tracking the study’s progress and anticipating when results might influence clinical practice and market dynamics.

Market Implications: This study update could influence AstraZeneca’s stock performance by potentially enhancing its oncology portfolio if successful. Positive outcomes might boost investor confidence, especially against competitors in the NSCLC treatment space. The collaboration with Parexel also highlights strategic partnerships in advancing cancer therapies.

The study is ongoing, with further details available on the ClinicalTrials portal.